应用31磷磁共振波谱成像评估帕金森病与进行性核上性麻痹患者的生物能量缺陷
横断面研究纳入30例特发性帕金森病、16例进行性核上性麻痹和25名健康对照,采用31磷磁共振波谱成像检测前脑和基底节高能磷酸代谢物。帕金森病组基底节高能磷酸代谢物较健康对照降低42%、较进行性核上性麻痹降低43%(p<0.0001),而进行性核上性麻痹组水平正常。形态学与代谢成像联合鉴别帕金森病与进行性核上性麻痹的准确度最高达0.93(95%CI 0.91-0.94)。
要点
- 帕金森病患者基底节高能磷酸代谢物较健康对照降低42%,较进行性核上性麻痹降低43%(p<0.0001)。
- 进行性核上性麻痹患者高能磷酸代谢物水平正常,提示线粒体功能障碍参与帕金森病而非进行性核上性麻痹。
- 形态学联合代谢成像鉴别帕金森病与进行性核上性麻痹准确度最高达0.93(95%CI 0.91-0.94)。
核心结论
- 线粒体功能障碍和生物能量耗竭参与特发性帕金森病的病理生理,但不参与进行性核上性麻痹。
- 形态学与代谢成像联合可作为神经影像引导下鉴别这些帕金森综合征的辅助诊断生物标志物。
研究设计与样本
- 横断面研究,共纳入30例特发性帕金森病患者、16例进行性核上性麻痹患者和25名健康对照。
- 所有受试者接受临床检查、结构磁共振成像以及前脑和基底节的31磷磁共振波谱成像。
主要发现
- 帕金森病患者高能磷酸代谢物显著降低,尤其在基底节较健康对照降低42%、较进行性核上性麻痹降低43%(p<0.0001)。
- 该结果未受脑形态学差异混杂。
- 进行性核上性麻痹患者高能磷酸代谢物水平正常。
- 形态学与代谢神经成像联合鉴别帕金森病与进行性核上性麻痹的准确度最高达0.93(95%CI 0.91-0.94)。
关键数值与推荐
- 本研究提供III级证据表明31磷磁共振波谱成像联合形态学磁共振成像可鉴别帕金森病与进行性核上性麻痹。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Bioenergetic disturbance, mainly caused by mitochondrial dysfunction, is an established pathophysiologic phenomenon in neurodegenerative movement disorders. The in vivo assessment of brain energy metabolism by 31phosphorus magnetic resonance spectroscopy imaging could provide pathophysiologic insights and serve in the differential diagnosis of parkinsonian disorders. In this study, we investigated such aspects of the underlying pathophysiology in patients with idiopathic Parkinson disease (PwPD) and progressive supranuclear palsy (PwPSP). METHODS: In total, 30 PwPD, 16 PwPSP, and 25 healthy control subjects (HCs) underwent a clinical examination, structural magnetic resonance imaging, and 31phosphorus magnetic resonance spectroscopy imaging of the forebrain and basal ganglia in a cross-sectional study. RESULTS: High-energy phosphate metabolites were remarkably decreased in PwPD, particularly in the basal ganglia (-42% compared with HCs and -43% compared with PwPSP, p < 0.0001). This result was not confounded by morphometric brain differences. By contrast, PwPSP had normal levels of high-energy energy metabolites. Thus, the combination of morphometric and metabolic neuroimaging was able to discriminate PwPD from PwPSP with an accuracy of up to 0.93 [95%-CI: 0.91-0.94]. DISCUSSION: Our study shows that mitochondrial dysfunction and bioenergetic depletion contribute to idiopathic Parkinson disease pathophysiology but not to progressive supranuclear palsy. Combined morphometric and metabolic imaging could serve as an accompanying diagnostic biomarker in the neuroimaging-guided differential diagnosis of these parkinsonian disorders. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that 31phosphorus magnetic resonance spectroscopy imaging combined with morphometric MRI can differentiate PwPD from PwPSP.
引用
- Prasuhn J, Göttlich M, Ebeling B, et al. Assessment of Bioenergetic Deficits in Patients With Parkinson Disease and Progressive Supranuclear Palsy Using 31P-MRSI. Neurology. 2022. PMID: 36195453. doi:10.1212/WNL.0000000000201288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。